Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acadia Pharmaceuticals

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics

The grant will support the development of the company’s disease modifying therapy for Parkinson's disease

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Neuron23 and QIAGEN partner to develop companion diagnostic for Parkinson’s disease

No laboratory tests are currently available for diagnosing the disease in non-genetic cases

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

MIT researchers develop AI model to detect Parkinson’s from breathing patterns

The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG received a £2.68m Innovative UK award to help fund research into treatments for Parkinson’s disease, motor neurone disease and other neurodegenerative diseases

- PMLiVE

NRG Therapeutics receives £2.68m Innovate UK Award

The funds will be used for research into new treatments for Parkinson’s and motor neurone disease

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

The Michael J Fox Foundation gives Asceneuron second research grant

Parkinson's disease affects an estimated seven to ten million people worldwide

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links